Device Trial Radar · NCT04904718
Real World Evaluation of Advisor Pro in Clinical Practice
Last checked: Nov 19, 2026Latest source record: Jan 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 2021
Primary completion
Dec 2021
Study completion Dec 2021
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- DreaMed
- First posted
- May 27, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the integration of the DreaMed Advisor Pro tool into a real-world clinical practice using both in person and virtual visits to assess benefits in glycemia, as measured by the glucose management indicator and other glucose metrics. To determine acceptability of the DreaMed Advisor Pro tool both from a person with diabetes as well as a health care provider perspective. To quantify the potential reimbursement potential that could be generated with use of the DreaMed Advisor Pro.
Conditions
- Type1diabetes
Interventions
DreaMed Advisor ProDevice
Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glucose control with the use of DreaMedTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.